Pharmacogenetic-guided dosing of coumarin anticoagulants: Algorithms for warfarin, acenocoumarol and phenprocoumon

British Journal of Clinical Pharmacology

Volumn 77, Issue 4, 2014, Pages 626-641

  Verhoef, Talitha I ^a   Redekop, William K ^b   Daly, Ann K ^c   Van Schie, Rianne M F ^a   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

acenocoumarol; CYP2C9; pharmacogenetics; phenprocoumon; VKORC1; warfarin

Indexed keywords

ACENOCOUMAROL; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR; CYTOCHROME P450 2C9; PHENPROCOUMON; PROTEIN C; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; VKORC1 PROTEIN, HUMAN;

ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; GENETIC ASSOCIATION; GENOTYPE; HEALTH INSURANCE; HEREDITY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT INDICATION; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DOSE CALCULATION; ECONOMICS; GENETICS;

ACENOCOUMAROL; ALGORITHMS; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2C9; DRUG DOSAGE CALCULATIONS; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENPROCOUMON; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84897909442     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12220     Document Type: Article

References (140)

1. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D,. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
2. Link KP,. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
3. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW,. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
4. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
5. Sun JC, Davidson MJ, Lamy A, Eikelboom JW,. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009; 374: 565-576.
6. Cannegieter SC, Rosendaal FR, Briet E,. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641.
7. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse TF,. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059-1063.
8. Little SH, Massel DR,. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2003; (4): CD003464.
9. Bjornara BT, Gudmundsen TE, Dahl OE,. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006; 88: 386-391.
10. White RH, Gettner S, Newman JM, Trauner KB, Romano PS,. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343: 1758-1764.
11. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG,. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193.
12. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198.
13. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L,. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004; 126: 1938-1945.
14. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E,. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
15. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LA, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH, The EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 2012; 13: 1405-1417.
16. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L,. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23: 83-91.
17. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ,. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166.
18. Federation of Dutch Anticoagulant clinics. Samenvatting medische jaarverslagen. 2011. Available at http://www.fnt.nl/media/docs/jaarverslagen/ Medisch-Jaarverslag-FNT-2011.pdf (last accessed 1 March 2013).
19. Sullivan PW, Arant TW, Ellis SL, Ulrich H,. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006; 24: 1021-1033.
20. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F,. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11: iii, iv, ix-66.
21. Merli GJ, Tzanis G,. Warfarin: what are the clinical implications of an out-of-range-therapeutic International Normalized Ratio?. J Thromb Thrombolysis 2009; 27: 293-299.
22. Schalekamp T, de Boer A,. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des 2010; 16: 187-203.
23. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL,. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-1866.
24. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-1896.
25. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR,. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-1532.
26. Demirkan K, Stephens MA, Newman KP, Self TH,. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000; 93: 448, 454; quiz 455.
27. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH, EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32: 1909-1917.
28. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH,. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86: 569-574.
29. Custodio das Dores SM, Booth SL, Martini LA, de Carvalho Gouvea VH, Padovani CR, de Abreu Maffei FH, Campana AO, Rupp de Paiva SA,. Relationship between diet and anticoagulant response to warfarin: a factor analysis. Eur J Nutr 2007; 46: 147-154.
30. Harder S, Thurmann P,. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-444.
31. Ufer M,. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-1246.
32. Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF,. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004; 61: 1258-1264.
33. Pengo V, Pegoraro C, Cucchini U, Iliceto S,. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006; 21: 73-77.
34. Kaminsky LS, Zhang ZY,. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
35. Thijssen HH, Flinois JP, Beaune PH,. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-1290.
36. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G,. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60: 173-182.
37. Jahnchen E, Meinertz T, Gilfrich HJ, Groth U, Martini A,. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 1976; 20: 342-349.
38. Kelly JG, O'Malley K,. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979; 4: 1-15.
39. Thijssen HH, Drittij MJ, Vervoort LM, de Vries-Hanje JC,. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70: 292-298.
40. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P,. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
41. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA,. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
42. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF,. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-59.
43. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR,. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5: 389-392.
44. Aithal GP, Day CP, Kesteven PJ, Daly AK,. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
45. Lindh JD, Holm L, Andersson ML, Rane A,. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65: 365-375.
46. Sanderson S, Emery J, Higgins J,. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
47. Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A,. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75: 394-402.
48. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH,. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14: 27-33.
49. Tassies D, Freire C, Pijoan J, Maragall S, Monteagudo J, Ordinas A, Reverter JC,. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87: 1185-1191.
50. Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L,. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11: 735-737.
51. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH,. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-66.
52. Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, Schwab M, Gleiter CH, Rane A, Roots I, Brockmoller J,. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14: 19-26.
53. Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A,. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004; 76: 409-417.
54. Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM,. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59: 213-219.
55. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW,. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-544.
56. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J,. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
57. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ, Mumford AD,. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6: 1663-1670.
58. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W,. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112: 1013-1021.
59. Yang L, Ge W, Yu F, Zhu H,. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 2010; 125: e159-166.
60. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR,. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: e312.
61. Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, Spiliotopoulou I, Travlou A,. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008; 9: 1631-1638.
62. Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, Patsch W, Oberkofler H,. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010; 66: 253-260.
63. Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP,. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis 2010; 21: 558-563.
64. Esmerian MO, Mitri Z, Habbal MZ, Geryess E, Zaatari G, Alam S, Skouri HN, Mahfouz RA, Taher A, Zgheib NK,. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol 2011; 51: 1418-1428.
65. Puehringer H, Loreth RM, Klose G, Schreyer B, Krugluger W, Schneider B, Oberkanins C,. VKORC1-1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol 2010; 66: 591-598.
66. Qazim B, Stollberger C, Krugluger W, Dossenbach-Glaninger A, Finsterer J,. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Thrombolysis 2009; 28: 211-214.
67. Geisen C, Luxembourg B, Watzka M, Toennes SW, Sittinger K, Marinova M, von Ahsen N, Lindhoff-Last E, Seifried E, Oldenburg J,. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol 2011; 67: 371-381.
68. Montes R, Nantes O, Alonso A, Zozaya JM, Hermida J,. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008; 143: 727-733.
69. Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC,. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol 2012; 158: 256-261.
70. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, van der Meer FJ, LE Cessie S, Wessels JA, VAN Schie RM, DE Boer A, Teichert M, Visser LE, Maitland-van der Zee AH, on behalf of the EU-PACT group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012; 10: 606-614.
71. Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH,. The EU-PACT group. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610-2612.
72. Zuchinali P, Souza GC, Aliti G, Botton MR, Goldraich L, Santos KG, Hutz MH, Bandinelli E, Rohde LE,. Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. J Thromb Thrombolysis 2013 (Epub ahead of print).
73. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P,. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270.
74. Kohnke H, Sorlin K, Granath G, Wadelius M,. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 2005; 61: 381-388.
75. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P,. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
76. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK,. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
77. van Schie RM, Wessels JA, Verhoef TI, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, Visser LE, Teichert M, Hofman A, Buhre PN, de Boer A, Maitland-van der Zee AH,. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose. Pharmacogenomics 2012; 13: 1917-1923.
78. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK,. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-547.
79. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL,. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
80. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H,. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
81. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F,. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
82. Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL,. Genotypes of the cytochrome P450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22: 191-197.
83. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL,. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
84. Consortium IWP, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA,. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
85. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R, Jr,. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-178.
86. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB,. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011; 118: 3163-3171.
87. Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard M,. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 2010; 125: e259-264.
88. Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdre L, Frascaro M, Palareti G,. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 2012; 68: 1167-1174.
89. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M,. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 2011; 12: 15-25.
90. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V,. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 782-787.
91. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC,. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80: 346-355.
92. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H,. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
93. Sasaki T, Tabuchi H, Higuchi S, Ieiri I,. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics 2009; 10: 1257-1266.
94. Harada T, Ariyoshi N, Shimura H, Sato Y, Yokoyama I, Takahashi K, Yamagata S, Imamaki M, Kobayashi Y, Ishii I, Miyazaki M, Kitada M,. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb Res 2010; 126: 183-190.
95. Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY,. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther 2011; 33: 1371-1380.
96. Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH,. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 2011; 56: 290-295.
97. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM,. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19: 226-234.
98. You JH, Wong RS, Waye MM, Mu Y, Lim CK, Choi KC, Cheng G,. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2011; 31: 113-118.
99. Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F,. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 2012; 107: 1083-1091.
100. Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T,. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Thromb Haemost 2012; 108: 1132-1140.
101. Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS,. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet 2011; 12: 80,2350-12-80.
102. Pavani A, Naushad SM, Rupasree Y, Kumar TR, Malempati AR, Pinjala RK, Mishra RC, Kutala VK,. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 2012; 12: 306-311.
103. Pathare A, Al Khabori M, Alkindi S, Al Zadjali S, Misquith R, Khan H, Lapoumeroulie C, Paldi A, Krishnamoorthy R,. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J Hum Genet 2012; 57: 665-669.
104. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G,. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008; 84: 722-728.
105. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Ruano G, Duconge J,. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics 2012; 13: 1937-1950.
106. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F, EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 2011; 90: 701-706.
107. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF,. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010; 87: 572-578.
108. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF,. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012; 107: 232-240.
109. van Schie RM, el Khedr N, Verhoef TI, Teichert M, Stricker BH, Hofman A, Buhre PN, Wessels JA, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, de Boer A, Maitland-van der Zee AH, Visser LE,. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics 2012; 13: 1239-1245.
110. Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B,. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS ONE 2012; 7: e37844.
111. Borobia AM, Lubomirov R, Ramirez E, Lorenzo A, Campos A, Munoz-Romo R, Fernandez-Capitan C, Frias J, Carcas AJ,. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS ONE 2012; 7: e41360.
112. Cerezo-Manchado J, Rosafalco M, Anton AI, Perez-Andreu V, Garcia-Barbera N, Martinez AB, Corral J, Vicente V, Gonzalez-Conejero R, Roldan V,. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thromb Haemost 2013; 109: 146-153.
113. Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF,. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 700-705.
114. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK,. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3: 137-145.
115. Caraco Y, Blotnick S, Muszkat M,. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-470.
116. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
117. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q,. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 2012; 9: 472-479.
118. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, Lee TH, Kuo CT, Sun FM, Chang YJ, Kuan PL, Chen YF, Charng MJ, Ray CY, Wu JY, Chen YT,. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84: 83-89.
119. Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E, Eby CS, King CR, Porche-Sorbet RM, Murphy CV, Marchand R, Millican EA, Barrack RL, Clohisy JC, Kronquist K, Gatchel SK, Gage BF,. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-1662.
120. McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC,. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit 2010; 32: 338-345.
121. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR,. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
122. Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD,. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011; 13: 509-518.
123. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF,. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005.
124. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH, COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010; 11: 1-9.
125. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF,. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2012; 12: 417-424.
126. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Diaz MQ, Fernandez-Capitan C, Ruiz-Gimenez N, Madridano O, Sillero PL, the PGX-ACE Spanish Investigators Group. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 2012; 13: 239,6215-13-239.
127. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, van der Zee AH,. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10: 1687-1695.
128. Howard R, Leathart JB, French DJ, Krishan E, Kohnke H, Wadelius M, van Schie R, Verhoef T, Maitland-van der Zee AH, Daly AK, Barallon R,. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clin Chim Acta 2011; 412: 2063-2069.
129. You JH, Tsui KK, Wong RS, Cheng G,. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009; 86: 540-547.
130. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL,. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010; 28: 61-74.
131. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ,. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
132. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P,. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
133. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH,. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18: 3758-3768.
134. Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, Nakamura Y,. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19: 4735-4744.
135. Dogliotti A, Paolasso E, Giugliano RP,. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs. warfarin. Clin Cardiol 2013; 36: 61-67.
136. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D,. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
137. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
138. Siegal DM, Cuker A,. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013; 35: 391-398.
139. Shah SV, Gage BF,. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123: 2562-2570.
140. You JH, Tsui KK, Wong RS, Cheng G,. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 2012; 7: e39640.